Reinduction with lapatinib followed by retreatment with trastuzumab-based therapy after disease progression multi-HER2 targeted therapies in HER2-positive metastatic breast cancer

Trial Profile

Reinduction with lapatinib followed by retreatment with trastuzumab-based therapy after disease progression multi-HER2 targeted therapies in HER2-positive metastatic breast cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Lapatinib (Primary) ; Trastuzumab
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Dec 2015 Status changed from not yet recruiting to recruiting, , according to University Hospital Medical Information Network - Japan record.
    • 14 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top